An evaluation of statistical approaches to postmarketing surveillance

Safety of medical products presents a serious concern worldwide. Surveillance systems of postmarket medical products have been established for continual monitoring of adverse events (AEs) in many countries, and the proliferation of electronic health record systems further facilitates continual monitoring for AEs. We review existing statistical methods for signal detection that are mostly in use in postmarketing safety surveillance of spontaneously reported AEs and we study their performance characteristics by simulation. We compare those with the likelihood ratio test (LRT) method (appropriately modified for use in pharmacovigilance) and use three different methods to generate data (AE based, drug based, and a modification of the method of Ahmed et al). Performance metrics include type I error, power, sensitivity, and false discovery rate, among others. The results show superior performance of the LRT method in almost all simulation experiments. An application to the FDA Adverse Event Reporting System database is illustrated using rhabdomyolysis-related preferred terms reported to FDA during the third-quarter of 2014 to the first-quarter of 2017 for statin drugs. We present a critical discussion and recommendations for use of these methods.

[1]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[2]  Bradley P. Carlin,et al.  Bayesian Hierarchical Modeling for Detecting Safety Signals in Clinical Trials , 2011, Journal of biopharmaceutical statistics.

[3]  B. Stricker,et al.  Serum sickness-like reactions to cefaclor. , 1992, Journal of clinical epidemiology.

[4]  G. D. Dal Pan,et al.  Evaluation of FDA safety‐related drug label changes in 2010 , 2013, Pharmacoepidemiology and drug safety.

[5]  Ram C Tiwari,et al.  Likelihood Ratio Test-Based Method for Signal Detection in Drug Classes Using FDA's AERS Database , 2013, Journal of biopharmaceutical statistics.

[6]  Qi Jiang,et al.  Sources of Safety Data and Statistical Strategies for Design and Analysis: Clinical Trials , 2018, Therapeutic innovation & regulatory science.

[7]  C Chuang-Stein,et al.  Organization and analysis of safety data using a multivariate approach. , 1992, Statistics in medicine.

[8]  Manfred Hauben,et al.  An Experimental Investigation of Masking in the US FDA Adverse Event Reporting System Database , 2010, Drug safety.

[9]  R. Tiwari,et al.  A Review of Statistical Methods for Safety Surveillance , 2014, Therapeutic innovation & regulatory science.

[10]  Richard C. Zink,et al.  Sources of Safety Data and Statistical Strategies for Design and Analysis: Postmarket Surveillance , 2018, Therapeutic innovation & regulatory science.

[11]  S. Evans,et al.  Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports , 2001, Pharmacoepidemiology and drug safety.

[12]  John Ihrie,et al.  openEBGM: An R Implementation of the Gamma-Poisson Shrinker Data Mining Model , 2017, R J..

[13]  Sushil Ghimire,et al.  Burden of hospitalizations related to adverse drug events in the USA: a retrospective analysis from large inpatient database , 2017, Pharmacoepidemiology and drug safety.

[14]  F Thiessard,et al.  False Discovery Rate Estimation for Frequentist Pharmacovigilance Signal Detection Methods , 2010, Biometrics.

[15]  Johan Hopstadius,et al.  Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery , 2011, Statistical methods in medical research.

[16]  William DuMouchel,et al.  Empirical bayes screening for multi-item associations , 2001, KDD '01.

[17]  Chieko Ishiguro,et al.  Post‐market drug safety evidence sources: an analysis of FDA drug safety communications , 2012, Pharmacoepidemiology and drug safety.

[18]  F Thiessard,et al.  Pharmacovigilance Data Mining With Methods Based on False Discovery Rates: A Comparative Simulation Study , 2010, Clinical pharmacology and therapeutics.

[19]  A Lawrence Gould,et al.  Practical pharmacovigilance analysis strategies. , 2003, Pharmacoepidemiology and drug safety.

[20]  G. Niklas Norén,et al.  Good Signal Detection Practices: Evidence from IMI PROTECT , 2016, Drug Safety.

[21]  Kristina Juhlin,et al.  Performance of Stratified and Subgrouped Disproportionality Analyses in Spontaneous Databases , 2016, Drug Safety.

[22]  Qi Jiang,et al.  Sources of Safety Data and Statistical Strategies for Design and Analysis: Real World Insights , 2018, Therapeutic innovation & regulatory science.

[23]  G. Hommel A stagewise rejective multiple test procedure based on a modified Bonferroni test , 1988 .

[24]  Y. Hochberg A sharper Bonferroni procedure for multiple tests of significance , 1988 .

[25]  Kristina Juhlin,et al.  Comparison of Statistical Signal Detection Methods Within and Across Spontaneous Reporting Databases , 2015, Drug Safety.

[26]  S. Dudoit,et al.  Multiple Hypothesis Testing in Microarray Experiments , 2003 .

[27]  Ram Tiwari,et al.  Zero-inflated Poisson model based likelihood ratio test for drug safety signal detection , 2017, Statistical methods in medical research.

[28]  S. Holm A Simple Sequentially Rejective Multiple Test Procedure , 1979 .

[29]  G. D. Dal Pan,et al.  Estimating the extent of reporting to FDA: a case study of statin‐associated rhabdomyolysis , 2008, Pharmacoepidemiology and drug safety.

[30]  Richard Platt,et al.  Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. , 2004, JAMA.

[31]  D. Madigan,et al.  The role of data mining in pharmacovigilance , 2005, Expert opinion on drug safety.

[32]  Ismaïl Ahmed,et al.  Implementation of an automated signal detection method in the French pharmacovigilance database: a feasibility study , 2011, European Journal of Clinical Pharmacology.

[33]  Na Hu,et al.  Signal detection in FDA AERS database using Dirichlet process , 2015, Statistics in medicine.

[34]  S. Anderson,et al.  The FDA's sentinel initiative—A comprehensive approach to medical product surveillance , 2016, Clinical pharmacology and therapeutics.

[35]  Christy Chuang-Stein,et al.  The Practice of Pre-Marketing Safety Assessment in Drug Development , 2013, Journal of biopharmaceutical statistics.

[36]  Ismaïl Ahmed,et al.  Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting , 2009, Statistics in medicine.

[37]  M. Lindquist,et al.  A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions , 2002, Pharmacoepidemiology and drug safety.

[38]  Y. Benjamini,et al.  THE CONTROL OF THE FALSE DISCOVERY RATE IN MULTIPLE TESTING UNDER DEPENDENCY , 2001 .

[39]  Manfred Hauben,et al.  A mathematical framework to quantify the masking effect associated with the confidence intervals of measures of disproportionality , 2017, Therapeutic advances in drug safety.

[40]  Sania Amr,et al.  Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014 , 2018, Clinical pharmacology and therapeutics.

[41]  A. Bate,et al.  A Bayesian neural network method for adverse drug reaction signal generation , 1998, European Journal of Clinical Pharmacology.

[42]  Marianthi Markatou,et al.  A pattern discovery framework for adverse event evaluation and inference in spontaneous reporting systems , 2014, Stat. Anal. Data Min..

[43]  R. Tiwari,et al.  A Likelihood Ratio Test Based Method for Signal Detection With Application to FDA’s Drug Safety Data , 2011 .

[44]  Min Yi,et al.  Extended likelihood ratio test-based methods for signal detection in a drug class with application to FDA’s adverse event reporting system database , 2018, Statistical methods in medical research.

[45]  Richard Platt,et al.  The FDA Sentinel Initiative - An Evolving National Resource. , 2018, The New England journal of medicine.

[46]  Ram Tiwari,et al.  Likelihood ratio based tests for longitudinal drug safety data. , 2014, Statistics in medicine.

[47]  Jesse A Berlin,et al.  Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team , 2009, Clinical trials.